Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Free Cash Flow (2016 - 2025)

Sonoma Pharmaceuticals has reported Free Cash Flow over the past 16 years, most recently at -$811000.0 for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 244.05% year-over-year to -$811000.0; the TTM value through Dec 2025 reached -$3.7 million, down 2682.64%, while the annual FY2025 figure was -$168000.0, 93.0% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$811000.0 at Sonoma Pharmaceuticals, down from -$645000.0 in the prior quarter.
  • Over five years, Free Cash Flow peaked at $563000.0 in Q4 2024 and troughed at -$2.6 million in Q1 2023.
  • A 5-year average of -$921600.0 and a median of -$1.0 million in 2023 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 150.95% in 2024 and later plummeted 296.65% in 2025.
  • Year by year, Free Cash Flow stood at -$327000.0 in 2021, then dropped by 15.9% to -$379000.0 in 2022, then tumbled by 191.56% to -$1.1 million in 2023, then skyrocketed by 150.95% to $563000.0 in 2024, then tumbled by 244.05% to -$811000.0 in 2025.
  • Business Quant data shows Free Cash Flow for SNOA at -$811000.0 in Q4 2025, -$645000.0 in Q3 2025, and -$2.1 million in Q2 2025.